Introduction {#Sec1}
============

Altered glucose metabolism and elevated body weight may affect breast cancer (BC) prognosis \[[@CR1]\]. Plasma cholesterol levels may influence the risk of developing BC possibly because cholesterol is a precursor of steroid hormones \[[@CR2], [@CR3]\], and endogenous sex steroid hormones stimulate cell proliferation in BC \[[@CR4]\]. Changes in metabolic parameters related to body weight and glucose and lipid metabolism have been observed after a BC diagnosis \[[@CR5]--[@CR9]\]. However, data on how, when, and for how long these changes occur are far from being conclusive. Most studies are based on retrospective chart review \[[@CR7], [@CR8], [@CR10], [@CR11]\], and body weight is the only metabolic parameter evaluated. In other instances, data were obtained during pretreatment and treatment but not at diagnosis \[[@CR12]\]. Importantly, only two studies examined metabolic changes at prospectively established time points and beyond one year of follow-up \[[@CR9], [@CR13]\].

To address these limitations and to investigate factors potentially related to metabolic changes, we prospectively evaluated body weight and fat composition, and the glucose and lipid metabolism in women with early BC (EBC) before adjuvant therapy, during treatment, and 2 years after diagnosis.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

We enrolled women aged ≥18 years with histologically confirmed BC treated with adjuvant chemotherapy and/or hormonal therapy at the University of Naples Federico II from July 2009 to October 2013. We excluded patients with a confirmed diagnosis of type I or type II diabetes based on laboratory data \[[@CR21]\] and those taking medications that could affect lipids or insulin and glucose levels. This study was approved by the Ethics Committee of the University Federico II (IRB approval number 343/15), and the participants provided written informed consent to participate.

Data retrieval {#Sec4}
--------------

Demographics, tumor stage and size (T), nodal status (N), estrogen receptor (ER), grading (G) progesterone receptor (PR) and HER2/neu status, and tumor proliferation measured by ki67 labeling were collected. Body weight, height, and waist and hip circumferences were measured before treatment (baseline) and 3, 6, 9, 12, and 24 months thereafter. Waist and hip circumferences were measured as previously described \[[@CR14]\]. Body mass index (BMI) was calculated as weight divided by height squared, and the waist-to-hip ratio was calculated as waist circumference divided by hip circumference.

Laboratory assays {#Sec5}
-----------------

Fasting glucose (mg/dl), serum insulin (µUI/ml), glycosylated hemoglobin (HbA1c, %), total, HDL, and LDL cholesterol (mg/dl), and triglycerides (mg/dl) were measured on venous blood collected at the time of diagnosis, before cancer therapy (baseline). The homeostasis model assessment (HOMA) index was calculated as glucose (mg/dl) multiplied by insulin (µUI/ml) divided by 40. Blood samples were collected in standardized conditions after overnight fasting between 7 am and 10 am. All measurements were repeated 3, 6, 9, 12, and 24 months after baseline measurements.

Data analyses {#Sec6}
-------------

Analyses were conducted in R version 3.0.1. Quantitative variables were summarized with mean ± standard deviation (SD); frequencies (percentage) were used for qualitative variables. Anthropometric parameters (post-diagnosis body weight, BMI, waist and hip circumferences, and waist-to-hip ratio), blood metabolic profile (blood glucose, serum insulin, HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides), and tumor characteristics (T, N, G, Ki67, ER, PgR, HER2, and treatment) were compared at baseline between pre-menopausal and post-menopausal patients with Student's *t* test and Chi-square test for numerical and categorical variables, respectively. Non-parametric Spearman rho was used to assess correlations among primary tumor characteristics and baseline anthropometric and metabolic variables. To determine the longitudinal variation of anthropometric and metabolic parameters, we used a set of linear mixed models with patient-level random effect for the intercept and with the fixed effect of time coded continuously as the number of years from diagnosis. The following fixed effects were included: hormone receptor (HR) status, adjuvant treatment, menopause status, T, N, HER-2, age, and BMI. In each analysis, the significance of the interaction between type of treatment and time was tested and, if significant, the corresponding term was added to the model. The results of linear mixed models are expressed as adjusted yearly change in the corresponding outcome variable with 95 % CI. A two-sided *P* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Demographic, clinical, and biological characteristics {#Sec8}
-----------------------------------------------------

A total of 433 EBC patients (175 pre-menopausal and 258 post-menopausal) were enrolled in the study. The patients' baseline clinical and metabolic characteristics stratified for menopausal status are summarized in Table [1](#Tab1){ref-type="table"}. At diagnosis, compared to post-menopausal patients, pre-menopausal women were more likely to be leaner (mean body weight: 67.9 ± 13.2 vs. 71.6 ± 13.9 kg; *P* \< 0.001), to have a lower BMI (26.3 ± 5 vs. 29.4 ± 5.8 kg/m^2^; *P* \< 0.001), and to have a smaller waist circumference (87.3 ± 12.5 cm vs. 94.8 ± 14.7 cm, *P* \< 0.001), hip circumference (100.6 ± 10.8 cm vs. 106.2 ± 11.7 cm, *P* \< 0.001), and waist-to-hip ratio (0.87 ± 0.07 vs. 0.89 ± 0.09, *P* \< 0.001). Unsurprisingly, post-menopausal patients were more likely than pre-menopausal patients to have a lower glucose level (92.22 ± 14.88 mg/dl vs. 104.78 ± 33.09 mg/dl: *P* \< 0.001), lower HOMA index (2.46 ± 3.12 vs 3.29 ± 3.37, p = 0.006), lower HbA1c level (5.68 ± 2.62 vs. 6.16 ± 3.45; *P* = 0001), and a lower triglyceride level (87.89 ± 42.46 mg/dl vs. 123.1 ± 68.45 mg/dl; *P* \< 0.001). Insulin, cholesterol, HDL, and LDL levels were unrelated to menopausal status.Table 1Baseline patient clinical and metabolic characteristics stratified by menopausal statusPre-menopause (*n* = 173)Post-menopause (*n* = 258)*p* valueAge42.5 ± 5.561.1 ± 6.8\<0.001Body weight67.9 ± 13.271.6 ± 13.90.004Body mass index26.3 ± 529.4 ± 5.8\<0.001Waist circumference87.3 ± 12.594.8 ± 14.7\<0.001Hip circumference100.6 ± 10.8106.2 ± 11.7\<0.001Waist-to-hip ratio0.87 ± 0.070.89 ± 0.09\<0.001Glucose92.22 ± 14.88104.78 ± 33.09\<0.001Insulin11.56 ± 13.8912.78 ± 13.610.097HOMA index2.46 ± 3.123.29 ± 3.370.006HbA1c5.68 ± 2.626.16 ± 3.450.001Total cholesterol200.89 ± 38.57208.22 ± 40.650.081HDL cholesterol61.26 ± 16.8260.01 ± 18.460.388LDL cholesterol119.64 ± 37.07126.84 ± 39.370.393Triglycerides87.89 ± 42.46123.1 ± 68.45\<0.001

Table [2](#Tab2){ref-type="table"} shows the baseline tumor characteristics stratified for menopausal status in our patients. Pre-menopausal women were more likely than post-menopausal women to have a tumor that was ER positive (87.9 vs. 79.8 %; *P* = 0.036), PR positive (85.5 vs. 76.7 %; *P* = 0.026), and highly proliferating (mean ki67 32.2 ± 21.4 vs. 27.7 ± 19.9; *P* = 0.025). Nodal status, G, and HER 2 status were not related to menopausal status.Table 2Baseline tumor characteristics stratified by menopausal statusPre-menopause (*n* = 173)Post-menopause (*n* = 258)*P* valueTumor size Mean ± SD21.6 ± 14.420.7 ± 11.80.862 \<2 cm93 (54.4)136 (52.9)0.766 ≥2 cm78 (45.6)121 (47.1)Nodal status, *n* (%)0.073 Negative87 (50.9)131 (52.4) Positive84 (49.1)119 (47.6)Grading, *n* (%)0.745 G17 (4.1)13 (5.1) G257 (33.1)90 (35.6) G3108 (62.8)150 (59.3)Ki67 Mean ± SD32.2 ± 21.427.7 ± 19.90.025 ≤15 %55 (33.1)106 (42.7)0.062 \>15 %111 (66.9)142 (57.3)ER0.036 Negative21 (12.1)52 (20.2) Positive152 (87.9)206 (79.8)PgR0.026 Negative25 (14.5)60 (23.3) Positive147 (85.5)198 (76.7)HER20.700 Negative140 (81.4)214 (82.9) Positive32 (18.6)44 (17.1)Treatment, *n* (%)0.016Chemotherapy only25 (14.4)55 (21.3)Endocrine therapy only38 (22.0)75 (29.1)Chemotherapy followed by endocrine therapy110 (63.6)128 (49.6)*ER* estrogen receptor, *PgR* progesterone receptor

Adjuvant therapy differed significantly according to menopausal status (*P* = 0.016). In detail, pre-menopausal patients were more frequently treated with chemotherapy followed by endocrine therapy (63.6 vs. 49.6 %) and less frequently by chemotherapy alone (14.4 vs. 21.3 %) or hormonal therapy alone (22.0 vs. 29.1 %). Most patients (76 %), receiving chemotherapy alone, received combined sequential treatment with anthracycline and cyclophosphamide for 4 cycles and weekly paclitaxel for 12 weeks. All HER2-positive patients received trastuzumab for 18 consecutive cycles. Among post-menopausal patients, 22 (10.8 %), 82 (40.4 %), 35 (17.3 %), and 24 (11.8 %) received 5 years of anastrozole, letrozole, exemestane, and tamoxifen, and 13 (6.4 %), 17 (8.4 %), and 10 (4.9 %) received tamoxifen for 2 years followed by anastrozole, letrozole, and exemestane, respectively.

Mean change per year of anthropometric and metabolic variables after adjuvant treatment {#Sec9}
---------------------------------------------------------------------------------------

To characterize the pattern of anthropometric and metabolic changes occurring during the 24 months after diagnosis, we used linear mixed models after removing the effect of the following baseline variables: HR status, systemic adjuvant treatment, menopause status, tumor size, nodal status, HER-2, age, and BMI (Table [3](#Tab3){ref-type="table"}). Over a median follow-up of 14 months (range: 6 − 24 months), there was a statistically significant increase in weight (+0.72 kg/year, 95 % CI 0.32--1.11; *P* \< 0.001) and waist circumference (+1.53 cm/year, 95 % CI 0.85--2.22; *P* \< 0.001) in the overall population. In modeling hip circumference, there was a significant interaction effect between time and treatment (*F* for interaction 3.723, *P* = 0.025). In particular, only in patients receiving chemotherapy alone there was a statistically significant increase in hip circumference (+3.16 cm/year, 95 % CI 1.60--4.73; *P* \< 0.001). Among metabolic variables, there were statistically significant increases in plasma levels of LDL cholesterol (+5.4 mg/dl per year, 95 % CI 0.12--10.68; *P* = 0.045) and triglycerides (+10.73 mg/dl per year, 95 % CI 1.95--19.51; *P* = 0.017) in all patients. Cholesterol level was significantly increased in patients receiving chemotherapy alone (+21.26 mg/dl per year, 95 % CI 10.18--32.35; *P* = \< 0.001) but not in the other subgroups (*F* for interaction 4.03, *P* = 0.019). Lastly, no statistically significant changes in glucose metabolism markers, namely glucose and insulin levels and HbA1C protein, were observed. Among post-menopausal patients, women receiving hormonal therapy did not experience a statistically significant change in weight, waist or hip circumferences, LDL cholesterol, triglycerides, and glucose blood levels when compared to patients receiving chemotherapy only (data not shown). Importantly, in the same patients' group, there was not a statistically significant change in the anthropometric or metabolic parameters included in the study according to the type of hormonal therapy (data not shown).Table 3Mean change per year of metabolic variables adjusted for hormone receptor status, systemic adjuvant treatment, menopause, tumor dimension, nodal status, HER 2, age, and body mass indexMean change/year95 % CI*P* valueBody weight+0.720.32 to 1.11\<0.001Waist circumference+1.530.85 to 2.22\<0.001Hip circumference CT + OT+0.82−0.06 to 1.700.069 CT+3.161.60 to 4.73\<0.001 OT+0.72−0.46 to 1.900.233Glucose−0.83−3.52 to 1.860.545Insulin−0.55−2.30 to 1.190.531HbA1c−0.22−0.63 to 0.200.301Total cholesterol CT + OT+3.82−2.40 to 10.030.228 CT+21.2610.18 to 32.35\<0.001 OT+2.07−9.97 to 14.110.735HDL cholesterol−1.93−5.39 to 1.530.272LDL cholesterol+5.400.12 to 10.680.045Triglycerides+10.731.95 to 19.510.017*CT* chemotherapy, *OT* endocrine therapy

Discussion {#Sec10}
==========

In this study, we assessed metabolic changes occurring after BC diagnosis and explored factors potentially implicated in these variations. Our EBC patients gained weight during the first 2 years after diagnosis, with an increase of 0.72 kg/year regardless of menopausal status, type of adjuvant therapy delivered, body weight, or BMI at baseline. Consistent with our findings, most previous studies reported weight increase ranging from few grams to several kgs (see Table S1, supplementary material) \[[@CR5], [@CR12], [@CR13], [@CR15]--[@CR23]\] after BC diagnosis. Some authors have suggested that menopausal status influences the extent of weight gained during adjuvant therapy. Two studies reported that weight gain was more pronounced in pre-menopausal women than in post-menopausal women \[[@CR24], [@CR25]\], thereby implicating ovarian failure and menopause onset in weight variation \[[@CR15]\]. However, this finding is not confirmed by other studies \[[@CR10], [@CR24], [@CR26], [@CR27]\]. We did not detect any difference in the extent of weight increase in relation to menopausal status or to age at diagnosis. The median age of our pre-menopausal patients was 42 years, and it is possible that the impact of treatment-related amenorrhea (due to chemotherapy or ovarian function suppression) on body weight may have been masked by a pretreatment peri-menopausal hormone status in most of them. In a much younger cohort of patients, the impact of drug-related amenorrhea might have been more pronounced.

In previous studies \[[@CR18], [@CR19], [@CR28]\], women gained more weight with chemotherapy than with hormonal therapy or radiotherapy. All our patients received adjuvant systemic treatment and, importantly, weight gain was unrelated to the type of systemic therapy delivered. The most frequent hormonal agent given in earlier studies was tamoxifen \[[@CR18], [@CR19], [@CR28]\]. Aromatase inhibitors for post-menopausal and ovary suppression in addition to tamoxifen for pre-menopausal women were the most frequently used hormonal therapies in our patients (data not shown). We cannot exclude that hormonal agents that have completely different toxicity profiles affect differently the patient's metabolism and energy balance.

Our data show that weight increase is also associated to changes of fat body composition, namely an increase of waist circumference and hip circumference, especially in patients who received chemotherapy. Waist and hip circumference and waist-to-hip ratio are additional measures of body fat distribution and provide an index of both subcutaneous and intra-abdominal adipose tissue \[[@CR14]\]. Several studies reported a significant increase in fat mass and a change in body fat distribution during chemotherapy \[[@CR29]--[@CR32]\]. Interestingly, chemotherapy-induced weight gain and changes in body composition seem to occur in specific body zones, namely the legs, trunk, and arms, and lean body mass losses affect predominantly the legs and lower trunk \[[@CR28], [@CR33]\].

Our study confirms the occurrence of body composition changes during and after adjuvant treatment, especially in patients treated with chemotherapy alone \[[@CR15], [@CR29]--[@CR32]\]. Of note, our patients who received chemotherapy alone were mostly treated with longer-lasting regimens containing taxane and anthracyclines. It was suggested that chemotherapy, particularly anthracyclines, may impair muscle function by reducing mitochondrial respiratory efficiency and cytosolic adenosine triphosphate content \[[@CR34]\], which can accentuate fatigue and inactivity, and induce an increase of fat deposition in specific body areas \[[@CR34]\].

To our knowledge, ours is the first study to evaluate whether serum metabolic biomarkers are compromised by adjuvant treatment received after a diagnosis of BC. In our patients, LDL cholesterol and triglyceride levels significantly increased during the 2 years after treatment irrespective of the type of therapy delivered. Consequently, this effect could be due to diet or lifestyle changes after BC diagnosis rather than to a side-effect of treatment. In patients treated with chemotherapy only, there was a greater increase of total cholesterol, probably due to the extensive use of anthracyclines in this subgroup. Adjuvant therapy did not seem to affect glucose metabolism in our patients.

A limitation of our study is the lack of a control arm constituted by women receiving local therapy alone. However, our analysis reflects current clinical practice where it is highly unlikely for an EBC patient not to receive systemic adjuvant therapy after local therapy, and therefore our results are applicable to most patients. Furthermore, a case--control study specifically addressing this question is not realistic and, in any event, may not yield information helpful for daily clinical practice. Furthermore, we did not analyze other potential indicators of weight gain, namely energy expenditure, dietary factors, change in menopausal status or in sexual hormonal status during and after systemic chemotherapy, and psychological factors. Our cohort is relatively homogeneous in terms of race, education, and social status (most patients were well educated and employed or retired); consequently, our results may not be generalized to all EBC survivors in different geographic areas.

In summary, we observed important alterations of metabolism (increase in body weight, waist and hip circumferences, LDL, triglyceride, and total cholesterol serum levels) in our patients receiving adjuvant therapy. These alterations, regardless of the specific cause, persisted up to 24 months after diagnosis and, as such, may be responsible for the reduced survival of EBC patients. Patients should be counseled about the risk of weight gain and of an altered lipid profile after a BC diagnosis, and should be aware that adjuvant hormonal therapy alone may not necessarily prevent these metabolic alterations. Preventive measures to reduce the risk of increasing weight and to reduce or maintain a healthy lipid profile should be offered to women who decide to undergo adjuvant systemic treatment after a diagnosis of EBC and local treatment.
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